CRSP
Crispr Therapeutics AG
A biotech company that turns the CRISPR gene-editing discovery into medicines for serious inherited diseases. Its first approved therapy, Casgevy, treats sickle cell disease and beta-thalassemia by editing a patient's own blood stem cells. Co-founded in 2013 by Emmanuelle Charpentier — one of the scientists who shared the Nobel Prize for discovering CRISPR — along with Rodger Novak and Shaun Foy, the company takes its name directly from the gene-editing system it commercializes.
CINS: H17182108ISIN: CH03340811373 holders
Total Value
$948.95M
Total Shares
17.73M
Net Share Change
-2.94M
Activity
1 buying2 selling
Investor
Value
Shares
Weight
Change
